Mode
Text Size
Log in / Sign up

Acute Decompensated Heart Failure

Part of Heart Failure

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acute Decompensated Heart Failure

9 trials tracked for Acute Decompensated Heart Failure: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 557 citations.

9Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 2 Other / NA 4
  1. Phase 4 Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Completed · 557 cited
  2. Phase 4 Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy Completed
  3. Phase 3 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure Completed
  4. Phase 2 The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure Completed
  5. Phase 2 Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Completed
  6. N/A REducing 30-day ADMIssions in posT-discharge Subjects (READMIT) Completed
Show 3 more trials
  1. N/A Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) Completed
  2. N/A A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients Completed
  3. N/A Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Acute Decompensated Heart Failure: what the trials found

Clinical investigations have evaluated various pharmacological interventions for patients with heart failure. Acetazolamide was studied as an intervention in this patient population 2. Additionally, Nesiritide has been investigated in the context of heart failure management 3.

A large-scale trial assessed the impact of Aliskiren on outcomes including cardiovascular death or heart failure re-hospitalization within 6 and 12 months. The study reported specific counts of these events across different groups, with the clinical summary score showing consistent changes from baseline at 1, 6, and 12 months 4.

Recent results — preliminary, needs further review

  • Diuretic administration was associated with total urine sodium outputs of 1082 and 423 (p<0.001). The incidence of clinically significant acute kidney injury, severe electrolyte abnormality, symptomatic hypotension, or hypertensive emergency did not differ significantly between groups (p=0.43) 1.

For the clinician treating this condition

  • Acetazolamide and Nesiritide are established interventions investigated in heart failure populations [2, 3].
  • Aliskiren was evaluated for its impact on cardiovascular death and re-hospitalization rates over a 12-month period 4.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Heart Failure

Related studies from across the Heart Failure family.

Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients
Cardiology Meta-analysis
Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients High bilirubin levels linked to lower heart risk in some cases
This meta-analysis examined the association between serum total bilirubin and major adverse cardiovascular events in patients undergoing per…
New data suggests high bilirubin might protect patients with coronary heart disease from long-term risks, though the evidence is still early…
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Diabetes & Endocrinology Sys. Review
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Targeting protein acylation modifications via SIRT1 and HDACs may mitigate myocardial injury and inflammation
Drug Pipeline Sys. Review
Targeting protein acylation modifications via SIRT1 and HDACs may mitigate myocardial injury and inflammation New ways to treat heart failure through protein modifications
This narrative review explores how protein acylation modifications, including acetylation and lactylation, regulate metabolic signaling in c…
Scientists identify how targeting specific protein changes can help repair heart tissue and reduce inflammation in patients with heart disea…
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm
Cardiology Guideline
Percutaneous transcatheter closure using an Amplatzer Muscular VSD Occluder treats left ventricular pseudoaneurysm Transcatheter Closure Shows Promise for Heart Failure Patients
This case report describes a 75-year-old male with heart failure and a left ventricular pseudoaneurysm successfully treated via percutaneous…
A new procedure using a transcatheter occluder may offer a safe way to treat heart failure caused by a specific heart wall defect.
Remote cardiac rehabilitation supported by mHealth improves exercise capacity in patients with heart failure
Cardiology Meta-analysis
Remote cardiac rehabilitation supported by mHealth improves exercise capacity in patients with heart failure Virtual cardiac rehab improves exercise capacity for heart failure patients
Researchers evaluated the impact of structured, remote, and hybrid cardiac rehabilitation programs compared to usual care or center-based mo…
Remote and hybrid heart rehabilitation programs using mobile health tools can improve walking distance and oxygen use in people with heart f…
Neural-immune-cardiovascular axis emerges as therapeutic target in atherosclerosis, hypertension, heart failure
Allergy & Immunology Sys. Review
Neural-immune-cardiovascular axis emerges as therapeutic target in atherosclerosis, hypertension, heart failure New pathways link nerves and immunity in heart disease
This systematic review synthesizes evidence on the neural-immune-cardiovascular axis in cardiovascular homeostasis and pathogenesis. It exam…
Scientists are mapping how the connection between your nervous system and immune cells may drive conditions like high blood pressure and hea…
Cognitive impairment affects 39% of chronic heart failure patients in pooled analysis
Cardiology Meta-analysis
Cognitive impairment affects 39% of chronic heart failure patients in pooled analysis Heart Failure Patients Face High Risk of Cognitive Impairment
This meta-analysis of 14 studies (5,127 patients) reports a pooled cognitive impairment prevalence of 39.3% in chronic heart failure. Risk f…
Nearly 40% of people with chronic heart failure experience cognitive impairment, with specific factors like age and depression increasing th…
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
Cardiology Guideline
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Persistent insomnia in heart failure is associated with higher anxiety and lower functional capacity
Cardiology RCT
Persistent insomnia in heart failure is associated with higher anxiety and lower functional capacity Persistent insomnia linked to higher anxiety in heart failure patients
This secondary analysis of a randomized trial involving 400 patients with heart failure identified distinct insomnia trajectories over 12 mo…
A new look at heart failure data shows that lasting sleep issues are tied to higher anxiety and lower physical ability.
GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF
Cardiology Meta-analysis
GLP-1 receptor agonists reduce HF worsening events in HFpEF but show no benefit in HFrEF GLP-1 drugs help heart failure with preserved ejection fraction
This meta-analysis of 11,234 patients with heart failure (HFpEF and HFrEF) found that GLP-1 receptor agonists significantly reduced HF worse…
GLP-1 receptor agonists improve outcomes in heart failure with preserved ejection fraction but not in reduced ejection fraction, according t…
MAGGIC Score Predicts Mortality Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge to Edge Repair
Cardiology Meta-analysis
MAGGIC Score Predicts Mortality Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge to Edge Repair New scoring system helps predict heart failure surgery risks
The MAGGIC score demonstrates significant predictive value for mortality in patients with functional or degenerative mitral regurgitation af…
A new risk score accurately predicts death rates for patients undergoing specific heart valve repairs, outperforming several standard models…
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions
Cardiology Sys. Review
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions Heart disease patients show measurable risk of developing various cancers
This systematic review and meta-analysis analyzed 4,759,695 patients to determine the prevalence of active cancer in individuals with variou…
New data shows that people with heart conditions like stroke or heart failure have a measurable rate of active cancer cases.

Questions about Acute Decompensated Heart Failure

Does furosemide plus hypertonic saline lower biomarker levels in acute decompensated heart failure?

Yes, furosemide plus hypertonic saline is linked to lower increases in biomarkers like NT-proBNP, IL-6, and sST2 after a saline load in ADHF patients, though baseline reductions may be similar.

Full answer →
Can natriuresis-guided protocols help with weight loss in acute decompensated heart failure?

Yes, natriuresis-guided protocols increase weight loss in acute decompensated heart failure, with a meta-analysis showing about 0.45 kg more weight loss at 48 hours compared to standard care.

Full answer →
Does a natriuresis-guided diuretic protocol shorten hospital stays for acute decompensated heart failure?

Evidence is mixed: one meta-analysis found natriuresis-guided protocols shortened hospital stays by about 1 day, but another found no significant difference.

Full answer →